The US Food and Drug Administration's Antimicrobial Drugs Advisory Committee endorsed the approval of the Global Alliance for TB Drug Development'spretomanid as part of a treatment-resistant tuberculosis regimen in a 14-4 vote, although panelists made clear at the 6 June meeting that they supported the regimen rather than the individual molecule.
Pretomanid is a nitroimidazooxazine antimycobacterial drug which the TB Alliance is developing as part of an oral combination with





